RecruitingNCT05935189

Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens

Establishment of a Tissue Registry for Hepatocellular Carcinoma Specimens for Genetic and Histologic Research

Sponsor

Nikomed Medical Center

Enrollment

500 participants

Start Date

Jul 1, 2023

Study Type

OBSERVATIONAL

Conditions

Hepatocellular Carcinoma

Summary

The goal of the study is to establish a cancer registry to facilitate research and assist in the identification of additional risk factors for hepatocellular carcinoma. The main objectives are: 1. provide a mechanism to store the information about subjects with hepatocellular carcinoma 2. use of tissue samples for translational/further research purposes

Eligibility

Plain Language Summary

Simplified for easier understanding

This study is creating a tissue bank (registry) of tumor samples from patients with hepatocellular carcinoma (HCC), the most common type of liver cancer, specifically among people of Armenian descent. The samples will be used for future research to better understand the disease. **You may be eligible if...** - You have been diagnosed with hepatocellular carcinoma (liver cancer), confirmed by biopsy - You are of Armenian descent - You have given your signed informed consent to participate **You may NOT be eligible if...** - You are unable or unwilling to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(1)

Nikomed Medical Center

Yerevan, Armenia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05935189

Related Trials

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

NCT0609677961 locations

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT044727671 location

SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

NCT072747741 location

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

NCT069022461 location